Navigation Links
By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
Date:3/31/2009

Washington, DC Researchers at Georgetown University Medical Center (GUMC) have been able to speed recovery and substantially reduce damage resulting from spinal cord injury in preclinical studies.

Their research, published online in Annals of Neurology and led by Kimberly Byrnes, PhD, shows that inflammation following injury causes the neurotoxicity that leads to lasting nerve cell damage, and that an experimental agent is able to block this inflammatory reaction.

"The findings we have made in this study may potentially be applicable to other neurological disorders, including stroke, head injury, Alzheimer's disease and Parkinson's disease," says senior investigator Alan I. Faden, MD, a professor of neuroscience and director of the Laboratory for the Study of Central Nervous System Injury at GUMC.

Faden says that the experimental agent they tested (CHPG), an activator of a type of glutamate receptor, is not ideal for human use because it cannot easily penetrate the blood-brain barrier. But he adds, "now that we know the biological target, a new drug could be designed that is better suited for clinical treatment of these neurodegenerative disorders."

CHPG shuts down activation of key immune cells in the brain known as microglia, which sense pathogens or damage in the spinal cord and brain. They helpfully foster the destruction of microbial invaders and clean up biological detritus that occurs after an injury, but researchers say they have a dark side as well they can worsen the damage by releasing toxic inflammatory factors.

"Under certain conditions, like spinal cord injury and brain trauma, microglia become activated," Faden says. "They release toxic chemicals that can kill healthy adjacent tissue, and this process can continue for months.

"We have found that six months after an injury, the expression of certain inflammatory factors in the spinal cord is 4-5 times normal levels," he says, adding that it has been shown that after human trauma, brain tissue can continue to be lost even more than a year after the injury. "Microglial related toxicity may contribute to this progressive loss," says Faden.

The study is a continuation of a long line of research by this investigative group that aims to stop that persistent damage. The team had previously found that microglial cells express a certain receptor, the group I metabotropic glutamate receptor 5 (mGluR5), on their surface. Further work showed that if these receptors were specifically activated on microglia, these immune cells would not produce the neurotoxins that led to cell death near the site of injury. CHPG serves to selectively activate the receptor, reducing microglial toxicity.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Community & Mission Hospital of Huntington Park Shutting Down Mission Campus, Terminating Workers
2. Pathway links inflammation, angiogenesis and breast cancer
3. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes
4. Inflammation, depression and antidepressant response: Common mechanisms
5. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
8. MassMutual Agent Honored by Insurance Industry for Extraordinary Service to Client
9. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
10. ABR-Affinity BioReagents Expands 100% Quality Guarantee
11. Inside job: new radioactive agents for colon cancer work inside cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... ... the Rose”: a charming tale of three animals, each with the desire to spread the ... the creation of published author, Ieshia Greaves, a mother and United States Marine with a ... of children and adults, there is a lesson for everyone to learn when reading this ...
(Date:9/25/2017)... Houston Tx (PRWEB) , ... September 25, 2017 ... ... 2017 Scholarship to Arizona State University student Ashlea Grabau. The $1000 student scholarship ... Centers Fall 2017 scholarship was awarded to Ashlea Grabau who is a medical ...
(Date:9/25/2017)... ... September 25, 2017 , ... SyncDog, Inc., the ... version 3.0, will be available in a managed cloud services model, available from ... with several new enhancements including support for caller ID and network sharing for ...
(Date:9/25/2017)... ... 2017 , ... The award is named in honor of Betty Pendler who ... award is given to those who exemplify the mission of Community Options and demonstrate ... of their choosing. Recent recipients of this award include Governor Tom Kean, Elaine Katz ...
(Date:9/25/2017)... ... 2017 , ... Order Custom Tee Shirts Online , Welldonedesigns.com ... to be concerned about garment selection, expensive graphic designers, substandard printing, and shipping. ... and shipped within 5-10 days. And every garment we ship is shipped ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: